Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …

Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

Aims Clinical trials have established the value of clopidogrel therapy in a wide spectrum of
patients with cardiovascular diseases. Both loss-and gain-of-function single nucleotide …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …